Advertisement
Organisation › Details
Aelin Therapeutics (BE)
Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches. Building on the solid science and a convincing data set, Aelin Therapeutics has succeeded in raising 27 M€, bringing together a strong group of well-reputed investors consisting of LSP (the Netherlands), PMV (Belgium), Novartis Venture Fund (Switzerland), Boehringer Ingelheim Venture Fund (Germany) and Fund+ (Belgium). These resources enable the company to build on its platform capabilities and develop its first products until the end of initial clinical development. *
Start | 2017-12-11 established (approx) | |
Predecessor | VIB (Flanders Interuniversity Institute for Biotechnology / Vlaams Instituut voor Biotechnologie) | |
Industry | BIOTECH | |
Industry 2 | Pept-in™ protein knockdown technology | |
Street | 1 Gaston Geenslaan Bioincubator Leuven | |
City | 3001 Leuven | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: VIB, Flanders Interuniversity Institute of Biotechnology. (12/11/17). "Press Release: New VIB Start-up Aelin Therapeutics Secures 27m € to Exploit Its Proprietary Pept-in Protein Knockdown Platform". | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Aelin Therapeutics (BE)
- [1] VIB, Flanders Interuniversity Institute of Biotechnology. (12/11/17). "Press Release: New VIB Start-up Aelin Therapeutics Secures 27m € to Exploit Its Proprietary Pept-in Protein Knockdown Platform"....
- [2] Life Sciences Partners (LSP). (12/11/17). "Press Release: LSP Leads EUR 27 mln Series A Financing of New VIB Start-up Aelin Therapeutics to Exploit Its Proprietary Pept-in Protein Knockdown Platform". Leuven....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top